Results 221 to 230 of about 75,579 (341)

Development of NAFLD‐Specific Human Liver Organoid Models on a Microengineered Array Chip for Semaglutide Efficacy Evaluation

Cell Proliferation, EarlyView.
Microporous array organ chips were integrated with commercially available well plates to develop organoid chip platforms, which enable modelling of hepatic physiology and non‐alcoholic fatty liver disease (NAFLD) pathogenesis, as well as evaluation of semaglutide therapeutics. ABSTRACT Progressive non‐alcoholic fatty liver disease (NAFLD) may culminate
Xiao‐yan You, Xiang‐yang Li, Hui Wang, Guo‐ping Zhao   +3 more
wiley   +1 more source

Baicalin mitigates polycystic ovary syndrome‑associated non‑alcoholic fatty liver disease by inhibiting the AR/SREBP1 axis. [PDF]

Int J Mol Med
Jin BH, Xu H, Zhang ZY, Fan YH, Jiang CY, Qi SL, Xiao CY, Fu XH, Qian LB.   +8 more
europepmc   +1 more source

Rational application of macrophage-specific LXR agonists avoids the pitfalls of SREBP-induced lipogenesis

, 2018
Jason A. Magida, Ronald M. Evans
openalex   +2 more sources

Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia

Nature, 2011
Christian M. Metallo, P. Gameiro, Eric L. Bell, Katherine R. Mattaini, Juanjuan Yang, Karsten Hiller, C. Jewell, Zachary R. Johnson, D. Irvine, L. Guarente, J. Kelleher, M. V. Heiden, O. Iliopoulos, G. Stephanopoulos   +13 more
semanticscholar   +1 more source

An interpretable machine learning model for predicting metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Patients with type 2 diabetes mellitus (T2DM) exhibit an elevated prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD) and are at greater risk of liver‐related adverse events. Existing non‐invasive tools show limited diagnostic performance in this population.
Zhuolin Zhou, Nan Gao, Jiaojiao Liu, Xuerong Ma, Zhijuan Ge, Cheng Ji   +5 more
wiley   +1 more source

C6ORF120 regulates hepatic lipid metabolism through PPAR signaling pathway in metabolic dysfunction-associated steatotic liver disease. [PDF]

Funct Integr Genomics
Wang P, Zhang J, Wang X, Liu H, Yi Y, Liu Y, Zhang J, Li X.   +7 more
europepmc   +1 more source

Metabolic dysfunction‐associated steatotic liver disease, insulin resistance and hepatocellular carcinoma: A deadly triad

European Journal of Clinical Investigation, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a major global cause of liver disease, driven by obesity and insulin resistance (IR). IR promotes hepatic lipid accumulation, inflammation and mitochondrial dysfunction, accelerating MASLD progression to fibrosis, cirrhosis and hepatocellular carcinoma (HCC).
Alfredo Caturano, Enes Erul, Roberto Nilo, Davide Nilo, Vincenzo Russo, Luca Rinaldi, Carlo Acierno, Erman Akkus, Katerina Koudelkova, Federica Cerini, Alessandro Rizzo, Ferdinando Carlo Sasso, Leonilde Bonfrate, Antonio Giordano, Hatime Arzu Yaşar, Caterina Conte   +15 more
wiley   +1 more source

10,12-Conjugated linoleic acid alleviates lipid accumulation in primary chicken hepatocytes via the ERK1/2-AMPK pathway. [PDF]

Poult Sci
Liu X, Yan P, Zhang H, Gao Q, Shang Y, Fu C.   +5 more
europepmc   +1 more source

Lipidomic profiling unveils sex differences in diabetes risk: Implications for precision medicine

European Journal of Clinical Investigation, EarlyView.
This study uncovered sex‐specific metabolic and lipidomic signatures of prediabetes. In PREVADIAB2 (n = 953), clustering by insulin traits revealed four phenotypes. Lipidomics showed women enriched in dihydroceramides and sphingomyelins, while men displayed a higher ceramide/sphingomyelin ratio. These sex‐metabolic phenotypes expose distinct lipidomes,
Ana F. Pina, Maria João Meneses, Fabrizia Carli, Rogério T. Ribeiro, Luís Gardete‐Correia, José M. Boavida, João F. Raposo, Amalia Gastaldelli, M. Paula Macedo   +8 more
wiley   +1 more source

Tet Transgene Activation is Disrupted in Lipogenic Triple Negative Breast Cancer Cells. [PDF]

ACS Synth Biol
Townsel A, Wu Y, Jaffe M, Shields C, Haynes KA.   +4 more
europepmc   +1 more source